Activity of pazopanib in chemo-resistant patients with germ cell tumors (GCT): First results of the open-label, single-group, phase II PAZOTEST-01 trial

被引：2
|
作者：
Giannatempo, Patrizia
Nicolai, Nicola
Fare, Elena
Raggi, Daniele
Piva, Luigi
Biasoni, Davide
Catanzaro, Mario
Torelli, Tullio
Stagni, Silvia
Maffezzini, Massimo
Crestani, Alessandro
Togliardi, Elena
Salvioni, Roberto
Gianni, Alessandro M.
Necchi, Andrea
机构：
[1] Fdn IRCCS Ist Nazl Tumori, Milan, Italy
[2] Natl Canc Istitute Milan, Milan, Italy
[3] Univ Milan, Milan, Italy
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2014年 / 32卷 / 04期
关键词：
D O I：
10.1200/jco.2014.32.4_suppl.376
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
376
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Apache: An open label, randomized, phase 2 study of durvalumab (Durva), alone or in combination with tremelimumab (Treme), in patients (pts) with advanced germ cell tumors (GCT): Results at the end of first stage
    Raggi, Daniele
    Giannatempo, Patrizia
    Mariani, Luigi
    Colecchia, Maurizio
    Calareso, Giuseppina
    Salvioni, Roberto
    Ali, Siraj Mahamed
    Ross, Jeffrey S.
    Chung, Jon
    Necchi, Andrea
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [22] Dacomitinib as first-line treatment of locally-advanced (LA) or metastatic penile squamous cell carcinoma (PSCC): Interim analysis of an open-label, single-group, phase 2 trial
    Necchi, A.
    Giardiello, D.
    Raggi, D.
    Giannatempo, P.
    Nicolai, N.
    Catanzaro, M.
    Torelli, T.
    Biasoni, D.
    Piva, L.
    Stagni, S.
    Calareso, G.
    Togliardi, E.
    Mariani, L.
    Salvioni, R.
    [J]. ANNALS OF ONCOLOGY, 2016, 27
  • [23] Phase II, open-label trial to assess QTcF effects, pharmacokinetics and antitumor activity of afatinib in patients with relapsed or refractory solid tumors
    L. Rhoda Molife
    Sarah M. Rudman
    Salma Alam
    Daniel S.-W. Tan
    Hartmut Kristeleit
    Gary Middleton
    David Propper
    Liz Bent
    Peter Stopfer
    Martina Uttenreuther-Fischer
    Gudrun Wallenstein
    Johann de Bono
    James Spicer
    [J]. Cancer Chemotherapy and Pharmacology, 2013, 72 : 1213 - 1222
  • [24] Phase II, open-label trial to assess QTcF effects, pharmacokinetics and antitumor activity of afatinib in patients with relapsed or refractory solid tumors
    Molife, L. Rhoda
    Rudman, Sarah M.
    Alam, Salma
    Tan, Daniel S. -W.
    Kristeleit, Hartmut
    Middleton, Gary
    Propper, David
    Bent, Liz
    Stopfer, Peter
    Uttenreuther-Fischer, Martina
    Wallenstein, Gudrun
    de Bono, Johann
    Spicer, James
    [J]. CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2013, 72 (06) : 1213 - 1222
  • [25] An Open-label Randomized Phase 2 study of Durvalumab Alone or in Combination with Tremelimumab in Patients with Advanced Germ Cell Tumors (APACHE): Results from the First Planned Interim Analysis
    Necchi, Andrea
    Giannatempo, Patrizia
    Raggi, Daniele
    Mariani, Luigi
    Colecchia, Maurizio
    Fare, Elena
    Monopoli, Francesco
    Calareso, Giuseppina
    Ali, Siraj M.
    Ross, Jeffrey S.
    Chung, Jon H.
    Salvioni, Roberto
    [J]. EUROPEAN UROLOGY, 2019, 75 (01) : 201 - 203
  • [26] A phase II single arm multi-center trial evaluating the efficacy of pembrolizumab in the treatment of patients (pts) with incurable platinum refractory germ cell tumors (GCT)
    Adra, Nabil
    Ammakkanavar, Natraj
    Radovich, Milan
    Vaughn, David J.
    Albany, Costantine
    Einhorn, Lawrence H.
    Hanna, Nasser H.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [27] Effect of Osimertinib and Bevacizumab on Progression-Free Survival for Patients With Metastatic EGFR-Mutant Lung Cancers A Phase 1/2 Single-Group Open-Label Trial
    Yu, Helena A.
    Schoenfeld, Adam J.
    Makhnin, Alex
    Kim, Rachel
    Rizvi, Hira
    Tsui, Dana
    Falcon, Christina
    Houck-Loomis, Brian
    Meng, Fanli
    Yang, Julie Li
    Tobi, Yosef
    Heller, Glenn
    Ahn, Linda
    Hayes, Sara A.
    Young, Robert J.
    Arcila, Maria E.
    Berger, Michael
    Chaft, Jamie E.
    Ladanyi, Marc
    Riely, Gregory J.
    Kris, Mark G.
    [J]. JAMA ONCOLOGY, 2020, 6 (07) : 1048 - 1054
  • [28] A PHASE-II TRIAL OF CIS DIAMMINE-1,1-CYCLOBUTANE DICARBOXYLATE PLATINUM (II) (CBDCA) IN PATIENTS (PTS) WITH CISPLATIN (DDP) RESISTANT GERM-CELL TUMORS (GCT)
    MOTZER, RJ
    TAUER, K
    BOSL, GJ
    GOLBEY, RB
    YAGODA, A
    [J]. PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, 1986, 27 : 188 - 188
  • [29] Pan-HER tyrosine-kinase inhibitors (TKI) dacomitinib and afatinib in penile squamous cell carcinoma (PSCC): Results from an ongoing open-label, single-group, phase 2 trial of dacomitinib in chemonaive patients (pts).
    Raggi, Daniele
    Necchi, Andrea
    Giannatempo, Patrizia
    Nicolai, Nicola
    Colecchia, Maurizio
    Calareso, Giuseppina
    Togliardi, Elena
    Crippa, Flavio
    Mariani, Luigi
    Perrone, Federica
    Pelosi, Giuseppe
    Salvioni, Roberto
    Sonpavde, Guru
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (02)
  • [30] An open-label, multicenter, phase I/II clinical trial of RP1 as a single agent and in combination with nivolumab in patients with solid tumors [IGNYTE]
    Aroldi, F.
    Middleton, M. R.
    Sacco, J. J.
    Milhem, M. M.
    Curti, B. D.
    VanderWalde, A. M.
    Baum, S. L.
    Samson, A.
    Chesney, J.
    Niu, J.
    Rhodes, T. D.
    Bowles, T. L.
    Olsson-Brown, A.
    Laux, D. E.
    Bommareddy, P. K.
    Menezes, L.
    Samakoglu, S.
    Pirzkall, A.
    Coffin, R. S.
    Harrington, K. J.
    [J]. ANNALS OF ONCOLOGY, 2021, 32 : S903 - S904
12345